The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA considers adding a dozen peptides to its bulk drug compounding list RAPS